Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

CX-3543, Cylene's lead rDNA biogenesis inhibitor, discussed at ASCO

June 6, 2007

Phase I study suggests promise for orally active VEGFR/FGFR tyrosine kinase inhibitor

June 6, 2007

First-in-human study of a potent pan-HER tyrosine kinase inhibitor from Pfizer

June 6, 2007

Encouraging findings emerge from first-in-man trial of peptibody AMG-386

June 6, 2007

New vascular-targeting agent moves forward to phase II trials based on positive phase I findings

June 6, 2007

Coronado licenses rights from Burnham to develop and commercialize Apogossypol

June 6, 2007

BNC-105 shows preclinical efficacy in prostate tumors

June 6, 2007

Orally active PARP inhibitor proves safe and effective in ovarian cancer

June 5, 2007

Phase II dose and schedule of R-547 selected based on phase I data

June 5, 2007

Good safety demonstrated for a new antisense inhibitor of Akt-1

June 5, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...